The government is to partner with German firm BioNTech, creating a Cambridge research hub to trial personalised cancer vaccines.
Professor Justin Stebbing is Editor-in-Chief of Nature’s cancer journal Oncogene, a visiting Professor of Cancer Medicine and Oncology at Imperial College, London and a Professor of Biomedical Sciences at ARU, Cambridge.
He originally studied medicine at Trinity College, Oxford, gaining a first class degree before moving to The Johns Hopkins Hospital in Baltimore, USA then returning to complete training at the Royal Marsden and St Barts Hospitals. In 2007 he was appointed a Senior Lecturer at Imperial College, London and a Consultant Oncologist at Imperial College Healthcare NHS Trust, then a Professor of Cancer Medicine and Oncology in 2009.
The nature of Justin's scientific contributions and international leadership in translational research were recognised by being awarded the NIHR’s first research translational professorship, becoming Editor-in-Chief of Oncogene - Springer Nature’s cancer journal - and elected a member of the American Society for Clinical Investigation.
He was also Chair of the Irish Cancer Society and a national charity, Action Against Cancer, was set up to support his research.
We are a not-for-profit citizen journalism publication. Our aim is to publish well-written, fact-based articles and opinion pieces on subjects that are of interest to people in East Anglia and beyond.
East Anglia Bylines is a trading brand of Bylines Network Limited, which is a partner organisation to Byline Times.
Learn more about us